Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...

In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

Up to 3,000 people will take part ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a ...

The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti ...

Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as ...

One of the reasons for the internal disagreement at the club was the fact that the nutritionist Eduardo Rauen, who has been ...

Congress has the power to make obesity treatment and weight management accessible to the communities that need it.

Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide ...

Can anything stop this high-flying drugmaker?